Growth Metrics

Compass Therapeutics (CMPX) Depreciation & Amortization (CF) (2023 - 2026)

Compass Therapeutics' Depreciation & Amortization (CF) history spans 4 years, with the latest figure at $15000.0 for Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 89.29% to $15000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $151000.0, a 73.74% decrease, with the full-year FY2025 number at $276000.0, down 53.14% from a year prior.
  • Depreciation & Amortization (CF) hit $15000.0 in Q1 2026 for Compass Therapeutics, down from $17000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for CMPX hit a ceiling of $194000.0 in Q1 2023 and a floor of $15000.0 in Q1 2026.
  • Historically, Depreciation & Amortization (CF) has averaged $121461.5 across 4 years, with a median of $143000.0 in 2024.
  • Biggest five-year swings in Depreciation & Amortization (CF): dropped 9.09% in 2025 and later crashed 89.29% in 2026.
  • Tracing CMPX's Depreciation & Amortization (CF) over 4 years: stood at $161000.0 in 2023, then fell by 13.04% to $140000.0 in 2024, then crashed by 87.86% to $17000.0 in 2025, then fell by 11.76% to $15000.0 in 2026.
  • Business Quant data shows Depreciation & Amortization (CF) for CMPX at $15000.0 in Q1 2026, $17000.0 in Q4 2025, and $19000.0 in Q3 2025.